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A steep rise in the popularity of mobile phones among children 
and adolescents in recent years has been reflected in both increased 
ownership and increased usage (1–3). One study (4) has indicated 
that most children start to use mobile phones when they are 
around 9–10 years old, but usage before school age is not 
uncommon. The increase in mobile phone use has raised concerns 
about possible adverse health effects. Brain tumors have been a 
main concern because when the handset is held to the head, the 
brain absorbs most of the radio frequency energy emitted by 
mobile phones. Moreover, it has been hypothesized (5) that chil-
dren may be more vulnerable to radio frequency electromagnetic 
fields (RF EMFs) because they have a developing nervous system, 
their brain tissue is more conductive than that of adults (because of 
its higher water content and ion concentration), and RF EMFs 
penetrate into regions that are deeper in their brains [because the head 
circumference is smaller in children compared with adults (5)]. 
Recent modeling studies (6,7) have indicated that about twice as 
much mobile phone energy is absorbed in the peripheral brain 
tissues of children aged 5–8 years as in adults.
The radio frequency radiation emitted by mobile phone hand-
sets has insufficient energy to directly damage DNA: It is nonion-
izing and its only known effect is heating. Hence, genotoxic effects 
such as DNA mutations or strand breaks cannot be directly linked 
to exposure to mobile phone radiation (8). The lack of genotoxicity 
of mobile phone radiation has been confirmed by experimental 
animal and laboratory studies (9,10). Overall, in vitro studies and 
experiments in mice [reviewed in (11)] have provided little evi-
dence that mobile phone radiation is carcinogenic.
To date, no study has addressed the association between mobile 
phone use and the risk of brain tumors among children and ado-
lescents. Studies in adults have shown no increase in risk among 
regular users but have been inconclusive regarding longer-term 
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heavy use of mobile phones (12). The recently published 
INTERPHONE study (13) found an increased risk for glioma 
among heavy users (cumulative call duration ≥ 1640 hours), but it 
is uncertain whether this reflects a true risk associated with the 
use of mobile phones or a spurious relationship due to recall bias 
or other methodological limitations (13,14). A study by Hardell 
et al. (15) reported that astrocytoma was much more common among 
adults who first used mobile phones before age 20 (odds ratio [OR] = 
5.2) or who first used cordless phones before age 20 (OR = 4.4).
In 2006, we set up CEFALO, an international case–control 
study of the relationship between mobile phone use and risk of 
developing brain tumors in children and adolescents. Participants 
were children aged 7–19 years in Denmark, Sweden, Norway, and 
Switzerland. We collected data by means of face-to-face interviews 
with the subjects and their parents.
Subjects and Methods
Study Population
CEFALO is an international case–control study performed in 
Denmark, Sweden, Norway, and Switzerland. The study period 
was approximately from January 1, 2004, through August 31, 2008, 
but varied slightly between study centers.
Case Eligibility and Ascertainment
All children and adolescents who were diagnosed during the study 
period with intracranial central nervous system tumors and who 
were aged 7–19 years at the time of diagnosis were eligible to 
become case patients. The brain tumors had to be coded as C71, 
D33.0–33.2, D33.9, D43.0–43.2, D43.9, or C72.9 according to the 
International Classification of Diseases, tenth revision (ICD-10) to be 
included. In addition, they had to fulfill the diagnostic criteria 
according to following morphology codes from the International 
Classification of Diseases for Oncology, third edition (ICD-O-3): epen-
dymoma (9383, 9391–9393), astrocytoma (9384, 9400–9401, 
9410–9411, 9420–9424, 9440–9442), primitive neuroectodermal 
tumor (PNET; 9470–9474, 9480, 9502–9504, 9508), other glioma 
(9380–9382, 9430, 9444, 9450–9451, 9460), other specified 
intracranial neoplasms (8743, 9064, 9071, 9080, 9161, 9390, 
9412–9413, 9492–9493, 9505–9507, 9560), or unspecified intra-
cranial neoplasms (8000–8005, 9990, 9999).
All diagnoses were either histologically confirmed or based on 
unequivocal diagnostic imaging. We examined medical records for 
case patients to confirm the diagnosis and to establish the date of 
diagnosis, which was used as reference date in the exposure assess-
ment. Date of diagnosis was defined as the date when the first 
diagnostic imaging was performed. Case patients were excluded if 
they were diagnosed with neurofibromatosis (Mb Recklinghausen; 
12 patients) or tuberous sclerosis (one patient). Study participants 
who were completely deaf before the reference date and children 
with severe mental retardation were excluded (two patients and 
two control subjects). In addition, families with insufficient 
language skills to complete an interview, as judged by a nurse, 
treating physician, or project administrator, were excluded (15 
patients and 36 control subjects).
Each country established procedures for identification of the 
case patients. In Denmark and Sweden, case identification was 
performed by a combination of reports from pediatric, oncology, 
and neurosurgery departments and from the population-based 
registries (the Danish National Cancer Registry, Childhood 
Cancer Registry, Pathology Registry, and National Patient 
Registry, and the Swedish Regional Cancer Registries, which also 
provide the data for the Swedish National Cancer Registry). In 
Norway, all case patients were identified from the population-
based Norwegian National Cancer Registry and verified by the 
responsible physician. In Switzerland, case patients aged younger 
than 16 years at diagnosis were identified through the Swiss 
Childhood Cancer Registry, and case patients aged 16–19 years at 
diagnosis were identified through neurosurgery clinics, pathology 
departments, and cantonal general cancer registries.
Control Eligibility and Selection
We randomly selected two control subjects per case patient using 
population registries in the participating countries, matched by age 
(in Denmark, Sweden, and Switzerland, by year and month of 
birth; in Norway, by year of birth), sex, and geographical region. 
In Switzerland, a two-stage random sampling procedure was 
applied for the selection of control subjects in the absence of a 
national population registry. First, a community was randomly 
determined within the same language region as each patient,  
and second, the control subject was randomly selected from the 
CONTEXT AND CAVEATS
Prior knowledge
No previous studies have examined whether mobile phone use 
among children and adolescents is associated with a difference in 
brain tumor risk.
Study design
The study included all 352 patients aged 7–19 who were diagnosed 
with brain tumors in 2004–2008 in Denmark, Sweden, Norway, or 
Switzerland and 646 age-, sex-, and region-matched controls. 
Mobile phone use was determined from interviews and, when 
available, from operator records. Odds ratios were determined for 
brain tumor incidence.
Contribution
Mobile phone users had no statistically significant difference in 
brain tumor risk compared with nonusers. Risk did not increase 
with the duration of mobile phone use. Nor was risk higher in the 
areas of the brain that came into closest proximity to a hand-held 
mobile phone.
Implications
The authors found little or no evidence that mobile phones 
increase brain tumor risk, and the single positive association could 
be explained by bias or chance.
Limitations
Most mobile phone usage data were based on the recall of chil-
dren or adolescents and their parents. Brain tumors are rare, and 
the study was not statistically powered to detect small risk 
increases. Amount and duration of mobile phone use was rela-
tively small and may have increased in this age-group since the 
time of this study.
From the Editors
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corresponding communal population registry. The reference date 
for control subjects was same as the date of diagnosis of the 
matched case patient.
Data Collection
Data collection started in June 2006 in all countries except Norway, 
where data collection started in December 2007. All case patients 
for whom physicians authorized contact and all control subjects 
were informed about the study and asked to participate (we did not 
receive authorization from the physicians of 19 case patients). The 
information letter explained the study focus on risk factors for 
brain tumors and did not mention mobile phones to minimize 
differential participation bias. The procedures varied between 
countries, depending on the requirements of local ethics review 
boards. If the case patient was deceased (36 cases), the parents were 
contacted at least 6 months after the death of the child, as requested 
by the treating physicians. The case patients and control subjects 
provided signed informed consent in all countries.
Whenever possible, the children were accompanied by at least 
one parent (preferably the mother) and were interviewed face to 
face by trained interviewers using a computer-assisted personal 
interview (CAPI) questionnaire (Denmark and Norway) or a paper 
version of the questionnaire (Switzerland and Sweden). In excep-
tional circumstances, telephone interviews were conducted with 
difficult-to-reach subjects (four control subjects) or an adapted 
paper version of the questionnaire was sent to the study partici-
pants (19 control subjects). Interviews with case patients and 
matched control subjects were mainly performed by the same 
interviewer. Interviewers from all centers received training at a 
joint workshop to ensure uniform data collection. The translations 
of the questionnaires were checked through back-translation to the 
master version (English), and the questionnaires were pilot tested 
in all participating countries. At all centers, control subjects who 
refused to participate in the study (n = 172) were asked to complete 
a short nonresponder questionnaire (85 were completed). A small 
number of nonparticipating case patients (n = 8) also completed 
the nonresponder questionnaire. Due to local ethical guidelines, it 
was not possible to send nonresponder questionnaires to case 
patients in Denmark when written refusals were received from case 
families. All case patients were interviewed within 5 years of diag-
nosis, and 63% were interviewed within 2 years of diagnosis.
Mobile Phone Exposure Assessment
All study participants were asked if they had ever spoken on a 
mobile phone more than 20 times during their lives and if the child 
ever owned a mobile phone before the reference date. Owners of 
a mobile phone were asked how many subscriptions they have had. 
For each subscription, the following information was asked: net-
work operator, when the subscription was started and stopped, use 
of hands-free devices, preferred side of head during use, number of 
calls per day, and duration of calls (both in predefined categories 
of use). Major changes in usage within a subscription were also 
recorded.
For calculating exposure surrogates, we did not consider mobile 
phone use that occurred within 6 months before the reference 
date. All subjects who had an average of at least one call per week 
for at least 6 months based on their self-reported amount of phone 
use were classified as regular users of mobile phones (16). 
Additional calculated exposure variables for regular users were 
time since first use of mobile phones (years), cumulative duration 
of subscriptions (years), cumulative duration of use (hours), and 
cumulative number of calls. All cumulative exposure surrogates 
were corrected for the use of hands-free devices. For all time pe-
riods for which the subject reported the use of hands-free 
devices, the amount of phone use was reduced by 80%, 50%, or 
20% depending on whether hands-free devices were used almost 
always, half of the time, or sometimes, respectively.
Study participants were asked to give consent to allow the 
researchers access to traffic data from mobile phone network oper-
ators. Data was provided by two network operators in Sweden, 
three in Denmark, and three in Switzerland. Operators were asked 
for data linked to a specific personal identification number, phone 
number or name, or a combination of any of the data given by the 
study participants. From the network operators, we received infor-
mation about number of calls, duration of calls, as well as subscrip-
tion start and end dates. In Switzerland, traffic data is deleted after 
6 months. Thus, only data covering the period after the reference 
date were available in Switzerland. Only time since first subscrip-
tion of phones could be used from the operator recorded data from 
Switzerland because this date is not routinely deleted.
Statistical Analysis
Odds ratios and 95% confidence intervals (CIs) were based on 
conditional logistic regression models for matched case–control 
studies (17). All statistical tests were two-sided. In the main 
analyses, the reference category for odds ratios consisted of sub-
jects who were nonregular users or nonusers of mobile phones. 
Time since first use of mobile phones, cumulative duration of 
subscriptions, cumulative duration, and number of calls were cate-
gorized based on the distribution of these variables in control 
subjects who were regular users; the 50th and 75th percentiles 
were chosen as cutoffs to allow for the skewed data distribution. 
P values for tests of linear trend (in risk for brain tumors in relation 
to exposure) were calculated by means of a two-sided Wald test for 
regression models in which exposure was included as a continuous 
variable, and all subjects in a category were assigned the median 
value of their corresponding category (18).
We checked the impact of the following potential confounders on 
our analyses: highest attained educational level of either mother or 
father as a measure of socioeconomic status (SES; low: elementary 
school not completed; intermediate: elementary school, diploma 
school, or apprenticeship; high: university or technical college), 
family history of cancer (yes, no), past medical radiation exposure to 
the head (yes, no), maternal smoking during pregnancy (yes, no), past 
head injuries (yes, no), use of baby monitors (ie, wireless baby mon-
itor or alarm used to remotely listen to sounds made by an infant) 
near the head (yes, no), use of cordless phones (cumulative duration 
and number of calls), contact with animals (yes, no), location where 
the child lived before age 6 (town or village with ≥200 inhabitants, 
farm, countryside), having siblings (yes, no), birth weight (continuous), 
born premature (yes, no), ever doctor-diagnosed asthma (yes, no), 
ever doctor-diagnosed atopic eczema (yes, no), and ever doctor-
diagnosed hay fever (yes, no). We decided a priori to include con-
founders in our model if the odds ratio for the regular use of mobile 
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phones changed by 10% or more compared with the unadjusted 
model (19,20). Because none of the confounders that we considered 
changed the risk estimate for regular use of mobile phones by 10% 
or more, none of these confounders were included in the conditional 
logistic regression models presented.
To evaluate consistency of the results, we conducted analyses 
that were stratified by country, age-group (<15and ≥15 years), sex, 
tumor morphology (astrocytoma and other glioma compared with 
all other tumors), tumor location (highly exposed temporal, frontal 
lobes, and cerebellum compared with other parts of the brain), 
time between diagnosis and interview (≥1.5 and <1.5 years), time 
lag between interview of case patients and matched control sub-
jects (>50 and ≤50 days), and latency periods of 2 and 5 years. 
Heterogeneity of the odds ratios between the strata was assessed 
with a likelihood ratio test that compared models that included 
only the main effects with those that included the interaction terms 
for the stratum-specific associations (21).
For the subset of subjects for whom operator data were avail-
able, analyses were made using the network operator recorded data 
to assess exposure. We used unconditional logistic regression 
models adjusted for geographical region, age and sex with operator 
recorded time since first subscription, cumulative duration of 
subscription, and, cumulative duration and number of calls as 
exposure variables. For the same subset of subjects, and for subjects 
for whom no operator recorded data were available, we also calcu-
lated unconditional logistic regression models using self-reported 
mobile phone use as exposure estimates, to compare the results for 
these two subsets of participants, and to allow an assessment of 
potential recall bias in self-reported mobile phone use.
In additional analyses, we compared the side of the head where 
users preferred to hold their mobile with the side of the head in 
which the tumor occurred by applying the method used in the 
INTERPHONE study (13). Each control subject was assigned the 
location of the tumor of the corresponding matched case patient. 
We considered the exposure to be ipsilateral if the phone was used 
predominantly on the same side as the tumor or on both sides of 
the head. We considered the exposure to be contralateral if the 
phone was used mostly on the side of the head opposite to the 
tumor. No laterality was assigned if the tumor was centrally lo-
cated, and separate analyses were made with these subjects.
We also analyzed the potential relationship between other 
sources of radio frequency exposure and the risk for brain tumors. 
Specifically, we analyzed whether subjects ever used baby monitors 
near the head, ever used cordless phones, and the cumulative 
duration and number of calls with cordless phones in the first 
3 years of use.
The software Stata/SE, version 10.1 (StataCorp, College 
Station, TX), was used for all analyses (22).
Time Trend Analysis
Because usage of mobile phones among children and adolescents 
has been a relatively recent and rapidly increasing phenomenon, we 
compared our study results with the observed time trends of brain 
tumor incidence. Most recent incidence data from among the four 
participating countries were available from Sweden (http://www.so
cialstyrelsen.se/statistik/statistikdatabas; accessed May 27, 2011). We 
used the observed brain tumor incidence data of Swedish children 
and adolescents aged 5–19 years from 1990 to 2008 and added 
hypothetical incidence rate trends derived from our risk estimates 
for regular mobile phone use based on self-reported and operator 
recorded data and estimated exposure prevalence (23). The pro-
portion of regular mobile phone users was estimated by combining 
data from the control subjects in CEFALO with subscriber data in 
Sweden (http://www.itu.int/ITU-D/ict/; accessed May 27, 2011).
Results
In total, 423 case patients and 909 potential control subjects were 
identified during the study period. Interviews were completed with 
352 (83.2%) eligible case patients and 646 (71.1%) eligible control 
subjects. The participation rates among case patients ranged from 
65.7% in Norway to 97.7% in Denmark and among control 
subjects from 58.2% in Norway to 76.3% in Sweden. The main 
reasons for nonparticipation were refusal to participate (18 case 
patients and 172 control subjects), inability to contact the subject 
(five case patients and 70 control subjects), and physicians’ denial 
of permission to contact some patients due to the severity of their 
disease (19 case patients). The median age of the study participants 
overall was 13 years and 46% were female (Table 1).
Among the 352 case patients, 162 (46.0%) were diagnosed with 
an astrocytoma, 21 (6.0%) with ependymoma, 30 (8.5%) with another 
glioma, 62 (17.6%) with primitive neuroectodermal tumors, 53 
(15.1%) with other specified intracranial neoplasms, and 24 (6.8%) 
with unspecified intracranial neoplasms.
Use of Mobile Phones
There were 265 (75.3%) case patients and 466 control subjects 
(72.1%) who reported having spoken on a mobile phone more 
than 20 times before the time when the case patient was diagnosed. 
Regular mobile phone use was reported by 194 (55%) case patients 
Table 1. Characteristics of case patients and control subjects
Case patients  
(n = 352)
Control subjects 
(n = 646)
Characteristic No. (%) No. (%)
Country  
 Denmark 85 (24.1) 170 (26.3)
 Sweden 138 (39.2) 228 (35.3)
 Norway 44 (12.5) 78 (12.1)
 Switzerland 85 (24.1) 170 (26.3)
Age at reference date, y*
 7–9 88 (25.0) 167 (25.9)
 10–14 144 (40.9) 265 (41.0)
 15–19 120 (34.1) 214 (33.1)
Sex  
 Female 162 (46.0) 293 (45.4)
 Male 190 (54.0) 353 (54.6)
Highest educational level of parents†
 Low 20 (5.7) 26 (4.0)
 Intermediate 188 (53.4) 336 (52.0)
 High 144 (40.9) 279 (43.2)
 Unknown 0 (0) 5 (0.8)
* Age at diagnosis for case patients and matched control subjects.
† Low: elementary school not completed; intermediate: elementary school, 
high school, or apprenticeship; high: university or technical college.
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and 329 (51%) control subjects. Brain tumor patients were not 
statistically significantly more often regular mobile phone users 
compared with control subjects (OR = 1.36; 95% CI = 0.92 to 2.02; 
Table 2). We also looked at various other exposure surrogates and 
observed somewhat elevated odds ratios without a clear exposure–
response relationship for the following exposure variables: time 
since first use (Ptrend = .37), cumulative duration of subscriptions 
(Ptrend = .14), cumulative duration of calls (Ptrend = .42), and cumula-
tive number of calls (Ptrend = .58). Children who started to use 
mobile phones at least 5 years ago were not at increased risk com-
pared with those who had never regularly used mobile phones 
(OR = 1.26, 95% CI = 0.70 to 2.28; Table 2).
For regular use of mobile phones, a stratified analysis by coun-
try yielded odds ratios greater than 1 for all countries except 
Norway (Table 3), although the observed pattern was in line with 
random variability (P for heterogeneity = .20). In stratified analyses 
according to age at diagnosis (<15 and ≥15 years), sex, tumor loca-
tion, tumor morphology, and time difference between case and 
control interviews, the odds ratios of regular use of mobile phones 
were not statistically significantly different between the strata.
We found no elevated risk among regular users of mobile 
phones when we looked at the parts of the brain with the highest 
radio frequency exposure, that is, the temporal and frontal lobes 
and the cerebellum (Table 3). On the other hand, we did find a 
statistically significant odds ratio for tumors in the parts of the 
brain with the lowest exposure to radiation among regular users of 
mobile phones (OR = 1.92; 95% CI = 1.07 to 3.44).
Operator Recorded Data
To confirm the results that we obtained from questionnaires, we 
also analyzed data on phone use, when available, from the mobile 
phone companies. Operator recorded data regarding the amount 
of time that had elapsed since the phone users’ first subscriptions 
were activated were available for 35% of case patients and 34% of 
control subjects who reported to have a mobile phone subscrip-
tion. For this subset of subjects, we found a statistically signifi-
cantly increased risk among users with the longest period since 
first subscription (OR = 2.15 [95% CI = 1.07 to 4.29] among 
24 case patients and 25 control subjects who had subscriptions for 
more than 2.8 years, Ptrend < .001; Table 4). We also tabulated 
records for cumulative duration of subscription, cumulative hours 
of use, and cumulative number of calls. For each of these cate-
gories, exposure–response trends were not statistically significant. 
Risk estimates based on self-reported data were similar for the 
subset of subjects for whom operator data were available compared 
with the corresponding risk estimates in the subset with no oper-
ator data.
Laterality of Mobile Phone Use
Because the absorbance of radiation from a mobile phone is highly 
localized to the side of the head where the phone is held, we also 
examined laterality of mobile phone use and occurrence of brain 
tumors. The odds ratio for brain tumor risk among ipsilateral reg-
ular users of mobile phones was not higher than the odds ratio of 
contralateral regular users (OR = 1.74, 95% CI = 0.91 to 3.33 and 
Table 2. Odds ratios (OR) and 95% confidence intervals (CI) of brain tumors associated with mobile phone use*
Variable
Case  
patients, No.
Control  
subjects, No. OR (95% CI) Ptrend†
Regular use‡    
 No§ 158 317 1.0 (referent)
 Yes 194 329 1.36 (0.92 to 2.02)
Time since first use, y    .37
 Never regular user 158 317 1.0 (referent)
 ≤3.3 95 165 1.35 (0.89 to 2.04)
 3.3–5.0 53 83 1.47 (0.87 to 2.49)
 >5.0 46 81 1.26 (0.70 to 2.28)
Cumulative duration of subscriptions, y§    .14
 Never regular user 158 317 1.0 (referent)
 ≤2.7 94 163 1.34 (0.89 to 2.01)
 2.8–4.0 45 78 1.45 (0.83 to 2.54)
 >4.0 52 81 1.58 (0.86 to 2.91)
Cumulative duration of calls, h§    .42
 Never regular user 158 317 1.0 (referent)
 ≤35 94 162 1.33 (0.89 to 2.01)
 36–144 48 81 1.44 (0.85 to 2.44)
 >144 49 81 1.55 (0.86 to 2.82)
Cumulative number of calls§    .58
 Never regular user 158 317 1.0 (referent)
 ≤936 94 163 1.34 (0.89 to 2.02)
 937–2638 50 80 1.47 (0.86 to 2.51)
 >2638 47 79 1.42 (0.79 to 2.53)
* Mobile phone use was defined as regular use, time since first use, cumulative duration of subscriptions, cumulative duration of calls, and cumulative number of 
calls.
† P values for tests of trend were calculated by means of a two-sided Wald test for regression models in which exposure was included as continuous variable, and 
all subjects in a category were assigned the median value of their corresponding category.
‡ “Regular use” was defined as use of a mobile phone at least once per week for a period of 6 months or more.
§ Six observations were dropped from the analysis because four participants had missing exposure data.
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OR = 2.07, 95% CI = 0.95 to 4.52, respectively; Table 5). For all 
exposure surrogates except time since first use of mobile phones, 
odds ratios of contralateral use in the highest exposure category 
were larger than the odds ratios for ipsilateral use. For those 
excluded from the laterality inverse exposure–response associa-
tions were observed.
Other Radio Frequency Electromagnetic Field Exposure 
Sources
We also evaluated other potentially relevant sources of radio 
frequency electromagnetic fields in early life. We found no evi-
dence for a relationship between ever use of baby monitors near 
the head and brain tumor risk (OR = 0.96, 95% CI = 0.50 to 1.86; 
Table 6). In addition, children’s use of cordless phones was not 
related to brain tumor risk (for the group with the highest amount 
of cordless phone use [>70 hours], OR = 1.18, 95% CI = 0.65 to 
2.14; Table 6).
Evaluation of Time Trends
We also examined the age-adjusted brain tumor incidence rates 
among Swedish children and adolescents aged 5–19 years from 
1990 to 2008 including hypothetical incidence rate trends 
(Figure 1). In these estimates, we made the assumption that reg-
ular use of mobile phones increases the risk of brain tumors by 
36% (based on self-reported exposure; Table 2) or 115% after 
3 years of regular mobile phone use (based on operator recorded 
exposure; Table 4). A risk estimate of 2.15 after 3 years of regular 
mobile phone use is expected to increase the incidence rate by 
about 50% in the last 10 years based on the proportion of regular 
users in our study collective. No such trend was observed in the 
incidence rates; in fact, rather the opposite trend was observed. 
This indicates that short-term use of mobile phone does not 
cause brain tumors in children and adolescents.
Discussion
The CEFALO study is the first case–control study of use of mobile 
phones and brain tumor risk in children and adolescents to our 
knowledge. Our primary analysis does not point to a statistically 
significantly increased risk for brain tumors in children that is as-
sociated with the use of mobile phones. There was no consistent 
exposure–response relationship either in terms of the amount of 
mobile phone use or by the location of the tumor. In a small subset 
of study participants with operator recorded data (n = 163), 
Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for stratified analyses
Stratum
Regular use*
No† Yes
Case 
patients
Control 
subjects  
Case 
patients
Control 
subjects
n n OR (95% CI) n n OR (95% CI)
Main analysis (for comparison) 158 317 1.0 (referent) 194 329 1.36 (0.92 to 2.02)
By country      
 Denmark 36 78 1.0 (referent) 49 92 1.49 (0.61 to 3.61)
 Sweden 57 109 1.0 (referent) 81 119 1.73 (0.87 to 3.41)
 Norway 21 31 1.0 (referent) 23 47 0.51 (0.18 to 1.41)
 Switzerland 44 99 1.0 (referent) 41 71 1.69 (0.79 to 3.61)
By age-group, y‡      
 <15 146 292 1.0 (referent) 86 140 1.42 (0.89 to 2.26)
 ≥15 12 25 1.0 (referent) 108 189 1.23 (0.59 to 2.58)
By sex      
 Female 61 123 1.0 (referent) 101 170 1.52 (0.81 to 2.84)
 Male 97 194 1.0 (referent) 93 158 1.27 (0.76 to 2.11)
By time between diagnosis and interview, y§      
 ≥1.5 122 257 1.0 (referent) 133 244 1.10 (0.75 to 1.61)
 <1.5 35 60 1.0 (referent) 61 85 1.53 (0.68 to 3.43)
By time between cases’ and controls’ interviews      
 Both controls within 50 d 69 151 1.0 (referent) 89 165 1.46 (0.81 to 2.62)
 One or more controls >50 d 89 166 1.0 (referent) 105 164 1.29 (0.75 to 2.20)
By tumor location      
 Temporal, frontal lobes, and cerebellum 83 155 1.0 (referent) 98 178 1.00 (0.58 to 1.72)
 Other than temporal, frontal lobes, and cerebellum 75 162 1.0 (referent) 96 151 1.92 (1.07 to 3.44)
By tumor morphology      
 Astrocytoma and other glioma 84 160 1.0 (referent) 108 189 1.14 (0.66 to 1.97)
 All except astrocytomas and other glioma 74 157 1.0 (referent) 86 140 1.65 (0.93 to 2.93)
By latency time, y      
 2 222 436 1.0 (referent) 130 210 1.34 (0.90 to 1.99)
 5 319 601 1.0 (referent) 33 45 1.36 (0.77 to 2.40)
* “Regular use” was defined as use of a mobile phone at least once per week for a period of 6 months or more.
† Reference category.
‡ Age of patients at diagnosis and comparable age for matched control subjects.
§ Based on unconditional logistic regression adjusted for geographical region, sex, and age.
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Table 6. Odds ratios (ORs) and 95% confidence intervals (CIs) of brain tumors associated with other radio frequency electromagnetic 
field exposure sources*
Variable
Case patients Control subjects  
No. No. OR (95% CI) Ptrend*
Ever use of baby monitors† near the head    
 No 335 611 1.0 (referent)
 Yes 17 35 0.96 (0.50 to 1.86)
Ever use of cordless phones    
 No 110 216 1.0 (referent)
 Yes 242 430 1.09 (0.81 to 1.45)
Cumulative duration of calls with cordless phones, h‡    .20
 Never user of cordless phones 102 189 1.0 (referent
 ≤23 70 135 0.98 (0.65 to 1.46)
 24–70 39 60 1.15 (0.71 to 1.87)
 >70 25 38 1.18 (0.65 to 2.14)
 Missing 116 224 0.94 (0.67 to 1.32)
Cumulative number of calls with cordless phones‡,§    .20
 Never user of cordless phones 102 189 1.0 (referent)
 ≤235 61 116 1.01 (0.66 to 1.53)
 236–704 48 79 1.07 (0.68 to 1.69)
 >704 27 39 1.21 (0.68 to 2.15)
 Missing 114 223 0.94 (0.67 to 1.31)
* P values for tests of trend were calculated by means of a two-sided Wald test for regression models in which exposure was included as continuous variable, and 
all subjects in a category were assigned the median value of their corresponding category.
† Wireless baby monitor or alarm to remotely listen to sounds made by an infant.
‡ In the first 3 years of use.
§ The 75th and 90th percentiles served as cutoffs because of broad categories.
however, time since the start of a mobile phone subscription was 
statistically significantly related to brain tumor risk.
Because of the methodological limitations of retrospective 
case–control studies and the absence of a known biological mech-
anism for carcinogenicity by low-dose microwave radiation, we 
considered several measures of exposure and conducted various 
stratified and sensitivity analyses to evaluate the consistency of our 
findings. Most results of these analyses were in line with the pri-
mary analysis and did not indicate an increased risk. However, we 
did observe a statistically significant trend of increasing risk with 
increasing time since first subscription when we used the data 
recorded by the network operators (Table 4). There was no 
Year
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Odds ratio=1.36 for being regular user
Odds ratio=2.15 for regular use
after 3 years
Figure 1. Gender and age-standardized incidence rates among Swedish children and adolescents aged 5–19 years between 1990 and 2008 (solid line). 
Dotted lines denote hypothetical incidence rate trends under the assumption that regular use of mobile phones increases the risk for brain 
tumors by 36% (odds ratio [OR] = 1.36) (without considering a latency period) and by 115% (OR = 2.15) after 3 years of regular mobile phone 
use (based on risk estimates in Tables 2 and 4), respectively.
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consistent trend with cumulative duration or number of calls. 
Operator recorded data are considered more reliable and less 
prone to recall bias than self-reported exposure data. However, our 
data were limited because we obtained operator recorded time 
since first subscription from only 35% of case patients and 34% of 
control subjects who reported to own a subscription. These 
proportions were even smaller for the other operator recorded 
exposure surrogates. In addition, operator data themselves have 
limitations. For example, the children had to remember their 
phone number(s) for us to be able to link to the operator data, and 
we still had to rely on interviews to account for whether recorded 
calls were made or taken with the use of hands-free devices. Also, 
we could obviously not verify from operator data whether the 
children themselves or others were using the mobile phone for any 
given recorded call. It is quite likely that the child occasionally lent 
out his or her phone to a peer or, in contrast, borrowed a phone 
from someone else. For underage study participants, subscriptions 
were sometimes held in the name of the parents and disentangling 
of the actual user(s) of each subscription may sometimes have been 
erroneous.
Reverse causality is another aspect to consider when interpret-
ing the observed increased risk for time since first subscription. 
Reverse causality exists if the condition of having a brain tumor 
itself prompted the use of mobile phones and thus the exposure of 
interest. For example, because of prodromal symptoms before 
diagnosis, some case patients may have appeared frailer than 
healthy children (24,25). To provide frail children better protec-
tion, parents may have given them a mobile phone to use in case 
of emergency or to keep in contact with friends in a situation with 
reduced mobility.
To estimate recall bias, we compared self-reported and objec-
tive mobile phone use data (26). We found that the duration and 
number of calls were overestimated by case patients (median 
ratio = 1.09, interquartile range [IQR] = 0.47–2.27 for number of 
calls and median ratio = 1.52, IQR = 0.63–4.28 for duration of 
calls) and control subjects (median ratio = 1.34, IQR = 0.63–5.36 
for number of calls and median ratio = 2.63, IQR = 0.89–10.06 
for duration of calls). The average extent of overestimation was 
not statistically significantly different between case patients and 
control subjects, suggesting that there was no substantial recall 
bias; however, the confidence limits were wide.
Because we did not find a clear exposure–response relationship 
in most of these analyses, the available evidence does not support 
a causal association between the use of mobile phone and brain 
tumors. Furthermore, some results of our sensitivity analyses 
make a causal relationship appear to be unlikely. For instance, 
odds ratios for brain tumors in analyses restricted to case patients 
with tumors in the temporal and frontal lobes and the cerebellum 
were not increased compared with odds ratios from the corre-
sponding main analyses. If there was a causal relationship, we 
would expect an increased risk specifically in these regions because 
the absorption of radio frequency energy from mobile phones is 
highly localized and has been shown to be considerably higher in 
the temporal and frontal lobes and the cerebellum compared with 
other parts of the brain (27). In fact, in laterality analyses, we 
found a higher risk for contralateral tumors than for ipsilateral 
tumors relative to where mobile phones were held and even found 
fewer tumors with a central or an unknown location, whereas if a 
causal relationship existed, highest risk for ipsilateral tumors 
would be expected (28). However, the number of participants in 
this analysis was small and confidence intervals were large. In ad-
dition, subjects’ statements about which side of the head they 
preferred to hold the mobile phone near during its use are often 
considered unreliable as was discussed in the INTERPHONE 
study (13).
Hardell and colleagues [eg, (15)] consistently found estimates of 
brain tumor risk to be of the same order of magnitude for both 
uses of mobile and cordless phones. In this study, however, we 
found no statistically significantly increased risk for brain tumors 
in relation to cordless phone use.
Our study has several strengths. Participation rates were high 
for case patients (83.2%) and for control subjects (71.1%) com-
pared with other case–control studies on mobile phone use and 
brain tumors in adults (13). Most importantly, when we used a 
logistic regression model to analyze the nonresponder interviews 
of control subjects by assessing the participation probabilities of 
users and nonusers of mobile phones, we did not find that the 
probability of participation was different between mobile phone 
users and nonusers according to case or control status [data not 
shown, see (26) for details]. Thus, the occurrence of relevant selec-
tion bias is unlikely in the CEFALO study.
To assess the possibility of confounding, we collected informa-
tion on the socioeconomic status of the parents, past radiation 
exposure, family history of cancer, animal contact, maternal 
smoking during pregnancy, and information about where the child 
lived until the age of 6 years. None of these potential confounders 
led to a noticeable change in the risk estimates. However, little is 
known about the etiology of childhood brain tumors. Apart from 
some rare genetic factors and high doses of ionizing radiation, no 
other risk factors have yet been established (29,30). Nevertheless, 
it cannot be excluded that we missed some potentially but still 
unknown relevant risk factors or confounders.
Our study also has limitations. We recruited case patients 
during a 4-year period in four countries. We chose the age range 
of the participants to maximize the probability of exposure to 
mobile phones. Nevertheless, because childhood brain tumors are 
rare (30), we could eventually include only 352 case patients and 
about two control subjects for each patient. Thus, the statistical 
power of the study to detect small risk increases was limited. 
In addition, we carried out multiple tests and some statistically 
significant results can be expected by pure chance underlining 
our cautious interpretation of the few positive findings.
There might also be an inherent limitation regarding the level 
of exposure in our study. Use of mobile phones is common among 
adolescents and children, and it is possible that the amount of use 
has increased since CEFALO was carried out. For example, 8% of 
participants aged 12–15 years at the time of diagnosis were already 
regular mobile phone users at the age of 10, whereas this was true 
for only 2% of participants aged 16–19 years at the time of diag-
nosis. Notably, most participants in our study used Global System 
for Mobile Communication (GSM) type mobile phones, whereas 
use of Universal Mobile Telecommunications System (UMTS) 
phones is becoming more popular and widespread nowadays. 
Recent studies have demonstrated that the average output power 
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of UMTS phones is 100–500 times lower than that of a typical 
GSM phones during average use (31,32). Thus, the actual time-
weighted exposure of the brain to radio frequency radiation may 
even have decreased in more recent years despite the increased use 
of mobile phones.
A recent study (33) that investigated the incidence of malignant 
and benign childhood central nervous system neoplasms in the 
Nordic countries found that the incidence rates of brain tumors in 
children aged 0–14 years remained stable at a high level during the 
last 22 years and concluded that major changes in environmental 
risk factors are unlikely. The same study, however, found a statis-
tically significant increase in incidence of 1.02% per year for chil-
dren aged 10–14 years. In England, no increase in the brain tumor 
incidence was observed between 1998 and 2007 among adolescents 
aged 10–20 years (33). Furthermore, a study that analyzed the 
brain cancer incidence trends in the United States reported stable 
time trends from 1992 to 2006 for both boys and girls who were 
younger than 20 years (34). These data are in line with our evalu-
ation of time trends of brain tumor incidence in Sweden and alto-
gether provide little support to the view that mobile phone use 
increases the risk of brain tumors.
In summary, we did not observe that regular use of a mobile 
phone increased the risk for brain tumors in children and adoles-
cents. However, in a small subset of study participants for whom 
operator recorded data was available, brain tumor risk was related 
to the time elapsed since the start of their mobile phone subscrip-
tions but was not related to the amount of use. The lack of an 
exposure–response relationship, given our finding that risk was 
related to neither the amount of mobile phone use and nor the 
location of the tumor, does not support a causal interpretation. 
Moreover, brain tumor incidence in Sweden has not increased 
among children and adolescents in the last few years. We cannot, 
however, rule out the possibility that mobile phones confer a small 
increase in risk and therefore emphasize the importance of future 
studies with objective exposure assessment or the use of prospec-
tively collected exposure data. We doubt that further retrospective 
studies based mainly on recall will contribute to clarification. We 
also recommend rigorous joint efforts of population-based cancer 
registries to monitor time trends in incidence rates including col-
lection of complete diagnostic data such as tumor topography, 
morphology, and laterality for at least the majority of patients. 
Because use of mobile phones has become very common among 
children and adolescents in most countries worldwide, even a 
small risk increase should be reflected in future incidence rate 
trends.
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